Research Topics
| G M GlennSummaryAffiliation: IOMAI Corporation Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunizationMikayel Mkrtichyan
Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, California, USA
DNA Cell Biol 27:19-24. 2008....
Transcutaneous immunization and immunostimulant strategiesGregory M Glenn
IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
Immunol Allergy Clin North Am 23:787-813. 2003..During the next 5 years, the challenge will be to conduct a development program that leads to safe and effective vaccination in the context of specific applications...- Immunostimulant patch enhances immune responses to influenza virus vaccine in aged miceMimi Guebre-Xabier
IOMAI Corporation, Gaithersburg, MD 20878, USA
J Virol 78:7610-8. 2004..Therefore, use of an LT-IS patch could be a new, safe, and simple immunization strategy that may significantly improve the outcome of influenza virus vaccination in the elderly... - Mass vaccination: solutions in the skinG M Glenn
IOMAI Corporation, Gaithersburg, MD 20878, USA
Curr Top Microbiol Immunol 304:247-68. 2006..The combination of the skin immune system, safe use of potent adjuvants and ease of delivery suggests that skin delivery of vaccines can address multiple unmet needs for mass vaccination scenarios... - Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge studyRobin McKenzie
Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, United States
Vaccine 25:3684-91. 2007..An enterotoxigenic Escherichia coli (ETEC) vaccine could reduce diarrhea among children in developing countries and travelers to these countries. The heat-labile toxin (LT) of ETEC is immunogenic but too toxic for oral or nasal vaccines... - Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneumGregory M Glenn
IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
Infect Immun 75:2163-70. 2007.... - Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patchGregory M Glenn
IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
Expert Rev Vaccines 6:809-19. 2007..In this review, we integrate these concepts, update the clinical data and look to the future... - Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skinGregory M Glenn
IOMAI Corporation, Gaithersburg, MD 20878, USA
Expert Rev Vaccines 2:253-67. 2003..These observations have moved into the clinic, highlighting the likelihood that skin delivery of vaccines will play an important future role in vaccine applications... - Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challengeG M Glenn
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
J Immunol 161:3211-4. 1998..Thus, clinically relevant immunity against mucosal toxin challenge can be achieved via the transcutaneous route... - Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvantsG M Glenn
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, D C 20307 5100, USA
Infect Immun 67:1100-6. 1999..Thus, TCI appears to induce potent, protective immune responses to both systemic and mucosal challenge and offers significant potential practical advantages for vaccine delivery... - Transcutaneous immunization: T cell responses and boosting of existing immunityS A Hammond
Walter Reed Army Institute of Research, Department of Membrane Biochemistry, Silver Spring, MD 20910 7500, USA
Vaccine 19:2701-7. 2001.... - Principles of transcutaneous immunization using cholera toxin as an adjuvantT Scharton-Kersten
Walter Reed Army Institute of Research, Department of Membrane Biochemistry, 14th and Dahlia Sts NW, Building 40, Rm 3049, Washington, DC 20307, USA
Vaccine 17:S37-43. 1999..Together these data further our understanding of the principles governing this new platform technology and support its integration into novel and existing human vaccine strategies... - Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cellsMimi Guebre-Xabier
IOMAI Corporation, Gaithersburg, Maryland 20878, USA
J Virol 77:5218-25. 2003.... 
Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patchDavid M Frerichs
IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
Vaccine 26:2782-7. 2008..The development of a simple, single-use, disposable device that is well-tolerated and allows disruption to be modulated represents an important step forward in physical penetration enhancement for the skin...- Needle-free skin patch vaccination method for anthraxGary R Matyas
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA
Infect Immun 72:1181-3. 2004..In addition, rPA alone exhibited adjuvant activity for TCI. Forty-six weeks after completion of TCI, 100% protection was observed against lethal anthrax challenge... - Transcutaneous immunization of domestic animals: opportunities and challengesS A Hammond
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, RM 2W 124, 503 Robert Grant Avenue, Washington, DC 20307 5100, USA
Adv Drug Deliv Rev 43:45-55. 2000..The prospect of TCI as a practical and broadly applicable approach to vaccination in veterinary medicine is discussed in the context of these challenges... - Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategyS A Hammond
IOMAI Corporation, Gaithersburg MD, 20878, USA
Crit Rev Ther Drug Carrier Syst 18:503-26. 2001..The near-term challenge will be to take this promising insight into successful product development... - Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneouslyFernando Güereña-Burgueño
Department of Enteric Infections, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
Infect Immun 70:1874-80. 2002..The data suggest that an ETEC vaccine for travelers delivered by a patch may be a viable approach worthy of further evaluation... - Improved immune responses to influenza vaccination in the elderly using an immunostimulant patchSarah A Frech
IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA
Vaccine 23:946-50. 2005..The data suggest that an LT IS patch may further enhance influenza vaccine immune responses in the elderly... - Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patchGregory M Glenn
Intercell USA, Inc, 20 Firstfield Road, Gaithersburg, MD 20878, USA
Vaccine 27:G60-6. 2009..The potent adjuvant, heat labile enterotoxin from E. coli (LT), placed over the immunization site in a patch, is a novel adjuvant strategy for immune enhancement, and was evaluated using an H5N1 injectable vaccine... - Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigenR L Richards
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, D C 20307 5100, USA
Infect Immun 66:2859-65. 1998..These results demonstrate that encapsulation of a lipid-containing particulate antigen, such as RTS, S, in liposomes containing lipid A can enhance both humoral and cellular immune responses... - GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvantJ Paul Zoeteweij
IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
J Immunol 177:1197-207. 2006..LT(G33D) is a promising candidate adjuvant for human trials of parenteral vaccines in general and for current i.d. vaccine development in particular... - Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccinesGregory M Glenn
Intercell USA, Inc, Gaithersburg, Maryland 20878, USA
Infect Immun 77:5206-15. 2009..If toxins truly exert barrier-disruptive effects as a key step in pathogenesis, then a return to classic toxin-based vaccine strategies for enteric disease is warranted and can be expected to have unexpectedly broad protective effects... - Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patchVladimir G Frolov
IOMAI Corporation, Gaithersburg, MD 20878, USA
Influenza Other Respi Viruses 2:53-60. 2008..Because of its effectiveness in vaccine delivery and its superior thermostable characteristics, the dry TIV patch represents a major advance for needle-free influenza vaccination... - Induction of protective immunity against lethal anthrax challenge with a patchRichard T Kenney
IOMAI, Gaithersburg, Maryland 20878, USA
J Infect Dis 190:774-82. 2004..To address critical unmet needs in biodefense against anthrax, we have designed a novel vaccine delivery system using a dry adhesive patch that simplifies administration and improves tolerability of a subunit anthrax vaccine... - Dose sparing with intradermal injection of influenza vaccineRichard T Kenney
IOMAI, Gaithersburg, MD 20878, USA
N Engl J Med 351:2295-301. 2004..Intradermal administration could be used to expand the supplies of influenza vaccine, but further studies are needed before this strategy can be recommended for routine use... - Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trialSarah A Frech
IOMAI Corporation, Gaithersburg, MD, USA
Lancet 371:2019-25. 2008..We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to the skin by patch in travellers to Mexico and Guatemala... - Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cellsIgor M Belyakov
Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1578, USA
J Clin Invest 113:998-1007. 2004..These results and previous clinical trial results support the observation that TCI is a safe and effective strategy for inducing strong mucosal antibody and CTL responses... - Adjuvants: progress, regress and pandemic preparednessGregory M Glenn
Expert Rev Vaccines 6:651-2. 2007
Research Grants
- TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTERGregory Glenn; Fiscal Year: 2003..Additionally, the Transcutaneous booster will decrease the risk of needle-sticks and related disease, and reduce personnel and equipment requirements related to tetanus immunization. ..
- Formulated Patch for Topical Influenza VaccineGregory Glenn; Fiscal Year: 2004..Needle-free may also aid in the extension of use of a flu patch into the pediatric population where influenza immunization is now recommended by the ACIP and will be a subsequent goal of this development program. ..
- Transcutaneous Immunization for an Anthrax VaccineGregory Glenn; Fiscal Year: 2005....